Background {#Sec1}
==========

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer that accounts for approximately 10 to 15% of all primary liver malignancies \[[@CR1], [@CR2]\]. Radical resection of the tumor is the potential curative treatment that prolongs survival outcomes \[[@CR3]\]. However, most patients lose the opportunity to undergo radical surgery due to advanced stage or extrahepatic metastasis at the time of diagnosis \[[@CR4]\]. Moreover, application of adjuvant therapies, such as chemotherapy and radiotherapy, is yet to be conclusively confirmed whether these provide significantly better survival outcomes \[[@CR5]\]. In consideration of increasing number of patients and limited therapeutic strategies, a better understanding of potential risk factors of ICC is essential to seek novel anti-tumor targets and to develop new treatment approaches.

Metastasis of tumor cells is one of the leading causes of mortality in ICC and occurs mainly through lymphatic vessels \[[@CR6]\]. In recent years, increasing experimental and clinicopathological studies indicated that lymphatic vessels undergo dynamic changes within the tumor, including tumor-associated lymphangiogenesis, that facilitate metastasis \[[@CR7]\]. Specific signaling pathways, such as vascular endothelial growth factor C (VEGF-C) and its cognate receptor VEGF receptor 3 (VEGFR-3) are confirmed to stimulate tumor-associated lymphangiogenesis, as well as lymph node metastasis in experimental tumor models \[[@CR8]--[@CR10]\]. Apart from that, lymphangiogenesis was found to be associated with increased frequency of tumor cells in lymphatics and lymph nodes in hilar cholangiocarcinoma \[[@CR11]\]. However, information regarding the role of tumor-associated lymphangiogenesis in progression and prognosis of ICC remains poor. In this study, we evaluated impact of tumor-associated lymphangiogenesis in patients with ICC, a highly malignant and aggressive primary liver cancer.

Methods {#Sec2}
=======

Patients and cancer tissues {#Sec3}
---------------------------

A total of 106 patients from Jan 2007 to Jul 2015 who underwent hepatic resection with curative intent for ICC were enrolled into the present study. The patients met the criteria as we described before \[[@CR12]\]. Briefly, patients who were pathological confirmed of ICC without distant metastasis were included. The present study was applied by the local ethics committee of Renji Hospital, Shanghai Jiao Tong University. Consents from individual patients were waived due to retrospective nature of the study.

Data collection {#Sec4}
---------------

All patients were followed up in the outpatient at regular intervals and those with unavailable data were visited by telephone inquiries or dropping-in follow up. The primary endpoint of this study was death of patients, and the second endpoint was recurrence of the tumor. Data of last follow-up investigation and recurrence of the tumor were collected for all patients.

Immunohistochemistry and assessment of micro-lymphatic vessel density {#Sec5}
---------------------------------------------------------------------

To analyze tumor-associated lymphangiogenesis, micro-lymphatic vessel density (MLVD) was determined by quantitative analysis of podoplanin-positive vessels as we described before \[[@CR12]\]. Four-micrometer thick tissue sections were collected and incubated with the monoclonal antibodies against podoplanin (rabbit monoclonal, 1:200; Abcam).The lymphatic vessels were counted in three most vascularized fields in non-consecutive sections in a block of tissue and were recorded as total number per unit area. The MLVD count of 4 to 12 vessels composed the low MLVD group according to the statistically greatest inverse proportion to the overall survival in accordance with the mean MLVD (12.59 vessels), whereas the others (≥13 vessels) were subjected to the high MLVD group.

Statistical analysis {#Sec6}
--------------------

The correlation between MLVD category and the clinicopathologic factors were evaluated using the chi-square test. The cut-off value for the MLVD was set by satisfying both the greatest range-dependent correlation with the overall survival and the mean MLVD value. Survival curves were estimated using the Kaplan--Meier method. For identification of independent prognostic factors, the Cox proportional hazard model was used in the univariate and multivariate analyses. All statistical analyses were performed using the SPSS (version 19.0). OR stands for odds ratio that attempts to quantify the strength of the association between different variables. Statistical significance was defined as *p* \<  0.05.

Results {#Sec7}
=======

Clinicopathological characteristics {#Sec8}
-----------------------------------

Of the 106 patients enrolled in the study, all patients had undergone liver resection and none received preoperative adjuvant chemotherapy or radiation therapy. The clinicopathological characteristics of the cohort are described in Table [1](#Tab1){ref-type="table"}. The cut-off range, \> 9 ng/ml (≥9.1 ng/ml), for AFP was set according to the hospital's serum positivity for the AFP, which was also the indicative value for hepatocellular carcinoma in some hospitals \[[@CR13]\]. Serum CA19--9 was also stratified according to the cut-off value of abnormal elevation (≥35 U/ml), which is a frequently used cut-off value for ICC in Chinese centers, such as Sun Yat-sen University Cancer Center \[[@CR14]\]. 42 patients (39.6%) were infected with hepatitis B virus (HBV) before the operation through laboratory tests. Alpha-fetoprotein (AFP), one of the specific tumor markers for hepatocellular carcinoma, was below the normal level in most patients with ICC (*n* = 78, 73.6%), while CA19--9 was above the cut-off value in majority of patients (*n* = 73, 68.9%) included in the study. During the operation, number of patients with largest tumor diameter over than 50 mm and multiple tumors nodes was 61 (57.5%) and 17 (16.0%), respectively. Presence of vascular invasion, lymph node metastasis and perineural sheath infiltration, which represented tumor progression, were found in 28, 48, 14 patients, respectively. The median follow-up of total patients was 22.1 months (maximum, 118 months). Tumor recurrence occurred in 72 patients by the end of follow-up.Table 1Clinicopathological characteristics of 106 patients with ICC enrolled in the studyClinicopathological CharacteristicsValue (%)Median age (years)60.0 (range, 35--82 years)Gender Male62 (58.5%) Female44 (41.5%)HBV infection Absent64 (60.4%) Present42 (39.6%)Preoperative AFP (μg/l)  \< 978 (73.6%)  ≥ 928 (26.4%)Preoperative CA19--9 (U/ml)  \< 3533 (31.1%)  ≥ 3573 (68.9%)Tumor size (mm)  \< 5045 (42.5%)  ≥ 5061 (57.5%)Tumor number Single89 (84.0%) Multiple17 (16.0%)Vascular invasion Absent78 (73.6%) Present28 (26.4%)Lymph node metastasis Absent58 (54.7%) Present48 (45.3%)Histologic differentiation Well or moderate52 (49.1%) Poor54 (50.9%)Distribution Unilobar41 (38.7%) Bilobar65 (61.3%)Perineural sheath infiltration Absent92 (86.8%) Present14 (13.2%)TNM stage I33 (31.1%) II15 (14.2%) III10 (9.4%) IV48 (45.3%)Tumor recurrence Absent34 (32.1%) Present72 (67.9%)

Tumor-associated lymphangiogenesis in ICC {#Sec9}
-----------------------------------------

Podoplanin-positive lymphatic vessels were detected within the tumors exhibiting both open and collapsed lumina in 106 ICC samples (Fig. [1](#Fig1){ref-type="fig"}a-d). In the Spearman's correlation test for range-dependent MLVD and survival, the greatest *p* value summary (\*\*\*\*; *p* \<  0.0001) was initially identified in a range of 4 to 12 (r = − 0.6589; 95% confidence interval \[CI\], − 0.8229 to − 0.3936), whereas the range 13 to 25 showed no significant correlation (r = − 0.1058; 95% CI, − 0.3814 to 0.1871; *p* = 0.4791; Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). In addition, the calculated MLVD was 12.59 ± 6.10 lymphatic vessels (range, 4 to 25 vessels). Therefore, the impact of the tumor-associated lymphangiogenesis on outcomes and prognosis, patients were divided into the high (\> 12 vessels) and low (≤12 vessels) MLVD groups.Fig. 1Immunohistochemical staining of podoplanin for evaluation of tumor-associated lymphangiogenesis in ICC. Podoplanin-positive lymphatic vessels exhibited both open and collapsed lumen, respectively (panel **a**, **b**; scale bar = 100 μm). Representative tissue sections for high (**c**) and low (**d**) MLVD (scale bar = 200 μm)Fig. 2Spearman's correlation test between MLVD and the overall survival. Spearman's correlation test indicated that the range 4 to 12 MLVDs is a distinctive range with significant inverse proportion to the overall survival (*P* \<  0.0001). However, the range 13 to 25 showed no significant proportion to the overall survival (*P* = 0.4791), indicating that all patients involved in this range obtained unfavorable prognosis regardless increase of the MLVD. Patients censored before 5 years of follow-up investigation were not includedTable 2Spearman's correlation test for stratification of prognostic subtypes according to the MLVDMLVDn (%)r (95% CI)P (two-paired)*P* value summary4 to 41 (1.3)NANANA4 to 57 (8.9)0.2041 (NA)0.5714NS4 to 611 (13.9)−0.4077 (−0.8166 to 0.2736)0.1013NS4 to 716 (20.3)−0.4604 (−0.7847 to 0.0619)0.0456\*4 to 819 (24.1)−0.5844 (− 0.8255 to − 0.1631)0.0086\*\*4 to 923 (29.1)−0.6729 (− 0.8531 to − 0.3494)0.0004\*\*\*4 to 1026 (32.9)−0.6035 (− 0.8074 to − 0.2709)0.0011\*\*4 to 1127 (34.2)−0.6182 (− 0.8124 to − 0.3005)0.0006\*\*\*4 to 1232 (40.5)−0.6589 (− 0.8229 to − 0.3936)\< 0.0001\*\*\*\*4 to 1337 (46.8)−0.6647 (− 0.8169 to − 0.4260)\< 0.0001\*\*\*\*4 to 1439 (49.4)−0.6619 (− 0.8119 to − 0.4299)\<  0.0001\*\*\*\*4 to 1544 (55.7)− 0.6436 (− 0.7930 to − 0.4212)\<  0.0001\*\*\*\*4 to 1648 (60.8)− 0.6377 (− 0.7838 to − 0.4248)\< 0.0001\*\*\*\*4 to 1750 (63.3)− 0.6220 (− 0.7709 to − 0.4085)\<  0.0001\*\*\*\*4 to 1856 (70.9)− 0.6630 (− 0.7915 to − 0.4784)\< 0.0001\*\*\*\*4 to 1960 (75.9)−0.6456 (− 0.7759 to − 0.4624)\< 0.0001\*\*\*\*4 to 2068 (86.1)−0.6752 (− 0.7897 to − 0.5152)\< 0.0001\*\*\*\*4 to 2169 (87.3)−0.6811 (− 0.7931 to − 0.5247)\< 0.0001\*\*\*\*4 to 2272 (91.1)−0.6789 (− 0.7895 to − 0.5256)\< 0.0001\*\*\*\*4 to 2376 (96.2)−0.6149 (− 0.7411 to − 0.4466)\< 0.0001\*\*\*\*4 to 2476 (96.2)−0.6149 (− 0.7411 to − 0.4466)\< 0.0001\*\*\*\*4 to 2579 (100)−0.5966 (− 0.7256 to − 0.4271)\< 0.0001\*\*\*\*Note: Patients censored before 5 years of follow-up were excluded. \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, \*\*\*\**p*\<0.0001Abbreviations: *MLVD* microlymphatic vessel density *CI* confidence interval. *NA* not applicable. NS, not significant

Correlation between MLVD and clinicopathological characteristics in ICC {#Sec10}
-----------------------------------------------------------------------

To determine the correlation between the degree of tumor-associated lymphangiogenesis and clinicopathological characteristics, we performed a further statistical analysis. The results of clinicopathological analysis are described in Table [3](#Tab3){ref-type="table"}. Patients' gender and preoperative tumor markers of AFP & CA19--9 were not significantly different between patients with "high MLVD" or "low MLVD". In contrast, patients with "low MLVD" were more likely to be infected with HBV preoperatively (29 out of 56 vs. 13 out of 50; *p* = 0.007). In addition, tumors with "high MLVD" showed more frequently lymph node metastasis (32 out of 50 vs. 16 out of 56; *p* \<  0.001) and higher level of TNM stage (40 out of 50 vs. 18 out of 56; *p* \<  0.001) compared with "low MLVD" tumors. Moreover, patients with "high MLVD" developed tumor recurrence more frequently than patients with "low MLVD" (49 out of 50 vs. 23 out of 56; *p* \<  0.001). Other clinicopathological parameters, including tumor size, distribution, number of tumor nodes, vascular invasion, histological differentiation and perineural sheath infiltration were not significantly different between both groups. Further, the MLVD value between patients with different TNM stages was compared as shown in Table [4](#Tab4){ref-type="table"}. It showed that patients with higher level of TNM stage revealed significantly higher MLVD value compared with lower level of TNM stage (15.19 ± 5.70 vs. 9.46 ± 5.05, *p* \<  0.001).Table 3Association between micro-lymphatic vessel density (MLVD) and clinicopathological characteristics of the patients with ICCClinicopathological CharacteristicsMLVD AnalysisLow MLVDHigh MLVD*p* valueNo. of patients5650Age (years)  \< 6035 (62.5%)21 (42.0%)0.035\*  ≥ 6021 (37.5%)29 (58.0%)Gender Male30 (53.6%)32 (64.0%)0.277 Female26 (46.4%)18 (36.0%)HBV infection Absent27 (48.2%)37 (74.0%)0.007\* Present29 (51.8%)13 (26.0%)Preoperative AFP (μg/l)  \< 940 (71.4%)38 (76.0%)0.594  ≥ 916 (28.6%)12 (24.0%)Preoperative CA19--9 (U/ml)  \< 3519 (33.9%)14 (28.0%)0.511  ≥ 3537 (66.1%)36 (72.0%)Tumor size (mm)  \< 5027 (48.2%)18 (36.0%)0.204  ≥ 5029 (51.8%)32 (64.0%)Tumor number Single50 (89.3%)39 (78.0%)0.114 Multiple6 (10.7%)11 (22.0%)Vascular invasion Absent41 (73.2%)37 (74.0%)0.921 Present15 (26.8%)13 (26.0%)Lymph node metastasis Absent40 (71.4%)18 (36.0%)\< 0.001\* Present16 (28.6%)32 (64.0%)Histologic differentiation Well or moderate29 (51.8%)23 (46.0%)0.552 Poor27 (48.2%)27 (54.0%)Distribution Unilobar24 (42.9%)17 (34.0%)0.350 Bilobar32 (57.1%)33 (66.0%)Perineural sheath infiltration Absent49 (87.5%)43 (86.0%)0.820 Present7 (12.5%)7 (14.0%)Tumor recurrence Absent33 (58.9%)1 (2.0%)\< 0.001\* Present23 (41.1%)49 (98.0%)TNM stage I/II38(67.9%)10(20.0%)\< 0.001\* III/IV18(32.1%)40(80.0%)\**p*\< 0.05 defined as statistical significanceTable 4Relationship between micro-lymphatic vessel density (MLVD) and TNM stage in patients with ICCCasesMLVD (mean ± SD)*p* valueTNM stage I/II489.46 ± 5.05*\< 0.001* III/IV5815.19 ± 5.70

Analysis of prognostic factors for overall and recurrence-free survival in ICC {#Sec11}
------------------------------------------------------------------------------

We further investigated specific clinicopathological variables predicting overall and recurrence-free survival after hepatic resection of ICC. The results of the univariate and multivariate analysis for overall and recurrence-free survival were described in Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}. In the univariate analysis for overall survival, MLVD, lymph node metastasis, and TNM stage were found to be significantly associated with overall survival (*p* \<  0.001, *p* = 0.003, *p* \<  0.001, and *p* \<  0.001, respectively). In the multivariate analysis, MLVD (*p* \<  0.001) and tumor size (*p* = 0.021) were determined as independent prognostic factors for overall survival after hepatic resection of ICC. For recurrence-free survival, MLVD was also identified as an independent risk factor through univariate and multivariate analysis (*p* \<  0.001 and *p* \<  0.001, respectively). In addition, though preoperative HBV infection, tumor size, number of tumor nodes, lymph node metastasis and TNM stage were also associated with recurrence-free survival in the univariate analysis (*p* = 0.009, *p* = 0.004, *p* = 0.049, *p* \<  0.001 and *p* \<  0.001, respectively), only tumor size (*p* = 0.010) revealed independent prognostic significance for recurrence-free survival.Table 5Univariate analysis of prognostic factors for overall survival in ICCVariableUnivariate analysisCategoryMedian survival*p* valueConfidence intervalAge\< 60 vs. ≥6024.1 vs. 19.90.3940.767--1.961GenderMale vs. Female19.3 vs. 26.10.0740.957--2.554HBV infectionAbsent vs. Present20.2 vs. 25.10.1180.411--1.106Preoperative AFP (μg/l)\< 9 vs. ≥919.5 vs. 29.40.4660.469--1.414Preoperative CA19--9 (U/ml)\< 35 vs. ≥3525.1 vs. 20.80.0750.952--2.849Tumor size (mm)\< 50 vs. ≥5028.4 vs. 17.50.003\*1.312--3.631Vascular invasionAbsent vs. Present24.9 vs. 14.40.0620.976--2.695Lymph node metastasisAbsent vs. Present30.7 vs. 11.8\< 0.001\*1.916--5.215Tumor numberSingle vs. Multiple23.6 vs. 14.40.2010.815--2.646Histologic differentiationWell/Moderate vs. Poor23.1 vs. 21.20.5610.719--1.838Perineural sheath infiltrationAbsent vs. Present22.6 vs. 19.00.6150.608--2.321DistributionUnilobar vs.Bilobar23.2 vs. 21.40.1270.894--2.457TNM stageI/II vs. III/IV34.3 vs. 12.0\< 0.001\*2.189--6.403MLVDLow vs. High34.8 vs. 7.9\< 0.001\*3.963--12.620\**p*\< 0.05 defined as statistical significanceTable 6Multivariate analysis of prognostic factors for overall survival in ICCVariableMultivariate analysisCategoryOdds ratioConfidence interval*p* valueTumor size (mm)\< 50 vs. ≥501.8991.121--3.2170.017\*Lymph node metastasisAbsent vs. Present1.1160.493--2.5260.791TNM stageI/II vs. III/IV1.6020.618--4.1500.332MLVDLow vs. High5.0052.569--9.752\< 0.001\*\**p*\< 0.05 defined as statistical significanceTable 7Univariate analysis of prognostic factors for recurrence-free survival in ICCVariableUnivariate analysisCategoryMedian survival*p* valueConfidence intervalAge\< 60 vs. ≥6019.6 vs. 16.30.2540.827--2.049GenderMale vs. Female16.7 vs. 20.00.6080.711--1.793HBV infectionAbsent vs. Present14.8 vs. 23.00.009\*0.319--0.847Preoperative AFP (μg/l)\< 9 vs. ≥915.3 vs. 25.90.6580.527--1.499Preoperative CA19--9 (U/ml)\< 35 vs. ≥3522.0 vs. 16.30.1220.897--2.504Tumor size (mm)\< 50 vs. ≥5025.0 vs. 12.90.004\*1.258--3.321Vascular invasionAbsent vs. Present20.2 vs. 12.00.3220.782--2.116Lymph node metastasisAbsent vs. Present27.4 vs. 6.8\< 0.001\*1.747--4.538Tumor numberSingle vs. Multiple19.9 vs. 8.30.049\*1.002--3.064Histologic differentiationWell/Moderate vs. Poor18.0 vs. 18.10.7270.689--1.706Perineural sheath infiltrationAbsent vs. Present14.5 vs. 18.60.9600.522--1.980DistributionUnilobar vs.Bilobar20.0 vs. 16.80.1690.867--2.269TNM stageI/II vs. III/IV31.0 vs. 7.3\< 0.001\*2.047--5.665MLVDLow vs. High30.7 vs. 3.9\< 0.001\*3.442--10.079\**p*\< 0.05 defined as statistical significanceTable 8Multivariate analysis of prognostic factors for recurrence-free survival in ICCVariableMultivariate analysisCategoryOdds ratio (Confidence interval)*p* valueHBV infectionAbsent vs. Present0.654 (0.386--1.107)0.114Tumor size (mm)\< 50 vs. ≥502.006 (1.180--3.410)0.010\*Tumor numberSingle vs. Multiple0.888 (0.486--1.623)0.700Lymph node metastasisAbsent vs. Present0.982 (0.446--2.160)0.963TNM stageI/II vs. III/IV1.748 (0.715--4.271)0.221MLVDLow vs. High3.762 (2.000--7.077)\< 0.001\*\**p*\< 0.05 defined as statistical significance

Impact of MLVD on overall and recurrence-free survival in ICC {#Sec12}
-------------------------------------------------------------

Since the abundance of MLVD revealed independent prognostic significance for both overall and recurrence-free survival, we further analyzed the influence of MLVD on survival through Kaplan-Meier method. The 1-, 3-, and 5-year survival of patients with "low MLVD" (*n* = 56) was 76.8, 66.8 and 48%, respectively. In contrast, the "high MLVD" group (*n* = 50) displayed 1-, 3-, and 5-year survival of only 20, 0 and 0%, respectively, (*p* \<  0.001), which was much worse than the "low MLVD" group (Fig. [3](#Fig3){ref-type="fig"}a). For recurrence-free survival (Fig. [3](#Fig3){ref-type="fig"}b), the 1-, 3-, and 5-year survival patients of "low MLVD" was 64.3, 53.8 and 50.4%, respectively, as compared with 4.0, 2.0 and 2.0%, respectively, in patients with "high MLVD" (*p* \<  0.001).Fig. 3Impact of different level of tumor-associated lymphangiogenesis and tumor size on overall and recurrence-free survival. (a) The overall survival of the high MLVD group (*n* = 50) was significantly worse than the low MLVD group (*n* = 56; *p* \< 0.001). (**b**) The recurrence-free survival of the high MLVD (n = 50) was also significantly unfavorable than the low MLVD group (n = 56; *p* \< 0.001). (c) Overall survival according to tumor size category revealed that patients with tumors ≥50 mm (*n* = 61) had worse outcomes than those with \< 50 mm (*n* = 45; *p* = 0.0017). (d) Patients with tumors ≥50 mm (n = 61) also had much worse recurrence-free survival compared with those with \< 50 mm (n = 45; *p* = 0.0018)

In addition to the abundance of MLVD, tumor size is also one of the risk factors for survival of patients with ICC based on the univariate and multivariate analysis. The 1-, 3-, and 5-year survival of patients with tumors\< 50 mm (*n* = 45) was 66.7, 54.1 and 44%, respectively, as compared with 37.7, 24.9 and 14.8%, respectively, in patients with tumors≥50 mm (*n* = 61; *p* \<  0.01; Fig. [3](#Fig3){ref-type="fig"}c). Furthermore, the recurrence-free survival of patients with tumors≥50 mm was also significantly inferior to patients with tumors\< 50 mm, with 1-, 3-, and 5-year survival of 23.0, 19.2, and 16.0%, in contrast to 53.3, 42.9 and 42.9%, respectively (*p* \<  0.01; Fig. [3](#Fig3){ref-type="fig"}d).

Discussion {#Sec13}
==========

ICC is a highly malignant neoplasm with a dismal prognosis due to insufficient evident symptoms at the early stage \[[@CR15]\]. Up to date, radical hepatic resection remains the only ideal curative treatment for ICC. However, only a minority of patients with ICC are candidates for radical surgical approaches, with a median survival of 6.3 to 16 months \[[@CR16]\]. Lack of appropriate medical approaches for ICC calls for further studies on its clinical and biological characteristics. Frequent lymph node metastasis is one of the major hallmarks of ICC that has been identified as a significant prognostic predictor \[[@CR17], [@CR18]\], while tumor-associated lymphangiogenesis in prognosis of ICC remains further confirmation.

In the present study, quantitative analysis of MLVD was performed by counting lymphatic vessels stained with podoplanin. Previously, studies of lymphatic vessels and dissemination have been limited due to lack of specific lymphatic markers. Vascular endothelial growth factor receptor-3 (VEGFR-3) was formerly considered as a marker for lymphangiogenesis. However, VEGFR-3 has also been shown to be expressed in blood vessel endothelium and cancer cells \[[@CR19], [@CR20]\]. In recent years, some specific markers, including LYVE-1 and podoplanin, have been identified. However, LYVE-1 has also been found to express on the endothelium of blood vessels \[[@CR21]\]. In contrast, podoplanin is expressed specifically in lymphatic endothelium and does not exist in blood vasculature \[[@CR22]\]. Therefore, podoplanin was chosen to evaluate tumor-associated lymphangiogenesis in the ICC specimens. Moreover, although not described in the present study, lymphatic vessels in adjacent healthy tissues were also evaluated, which ranged from 0 to 5. These vessels seem to play normal biological roles in the propulsion of the lymph circulation considering its no association with metastasis and prognosis of ICC. In addition, high expression of tumor-associated lymphangiogenesis was found to be closely associated with lymph node metastasis and recurrence, suggesting that tumor cells of ICC are likely to migrate along tumor-associated lymphatic vessels into lymph nodes, thus facilitating recurrence of the tumor that leads to poor prognosis. These findings are in line with several previous studies that reported association between lymphatic vessels and lymph node metastasis in mass-forming tumors \[[@CR23]--[@CR25]\].

In addition, it is noteworthy that patients with low expression of MLVD seemed to be more likely to be infected with HBV preoperatively (*p* = 0.007), which was identified as a prognostic factor for recurrence-free survival (*p* = 0.009). HBV infection has been considered associated with an increasing incidence of ICC in East Asia, where HBV is endemic \[[@CR26], [@CR27]\]. However, several studies found that HBV infection may be a favorable factor in patients with ICC. Zhou et al. \[[@CR28]\] suggested that the survival of HBV-associated ICC patients was better due to inhibited tumor invasiveness. Wu et al. \[[@CR29]\] regarded HBV infection as a favorable factor because of early detection of the unexpected tumor during chronic liver disease follow-up. On the contrary, Ahn et al. \[[@CR30]\] reported that 37 HBV-positive and 255 HBV-negative ICC patients showed no significant difference in their outcomes. Since the distribution of HBV infection in ICC was found to vary worldwide, the different results may be attributed to patients enrolled from various regions and different stages of tumor upon diagnosis. Thus, our results require validations in populations from different regions.

Recently, prophylactic lymph node dissection has been considered as a benign factor that might improve the prognosis of the patient with ICC \[[@CR31]\]. A study from Japan rendered that the wide dissection, including the regional and para-aortic lymph nodes, along with hemihepatectomy was found to be curative in the first 5-year survivor with periductal-infiltrating ICC \[[@CR32]\]. Since tumor-associated lymphangiogenesis is an important independent prognostic factor that deteriorates survival by promoting lymph node metastasis, intraoperative biopsy to evaluate extent of tumor-associated lymphangiogenesis may support decision for performance lymphadenectomy.

Moreover, tumor-associated lymphangiogenesis may serve as one of the novel therapeutic targets of ICC, of which the VEGF-C/VEGF-D-VEGFR3 axis is considered a major driver of tumor-associated lymphangiogenesis \[[@CR33]\]. In addition, other growth factors and signaling pathways are also involved in lymphangiogenesis. VEGF-A was found to promote lymphangiogenesis and lymph node metastasis in a mouse fibrosarcoma xenograft model \[[@CR34]\]. Platelet-derived growth factor B also induced tumor lymphangiogenesis and promoted lymph node metastasis in mice, but this could not be prevented using a VEGFR3-targeted antibody \[[@CR35]\]. While, transforming growth factor-β (TGF-β) has been reported to be a negative regulator of lymphangiogenesis in cancer. Inhibition of endogenous TGF-β signaling in mouse xenograft models of pancreatic adenocarcinoma induced lymphangiogenesis \[[@CR36]\]. Based on these findings, various tyrosine kinase inhibitors targeting VEGF, EGRF or FGF receptors such as sorafenib, sunitinib, regorafenib, etc. are under clinical trials for different types of tumor \[[@CR37]--[@CR39]\]. Since clinical trials and reports about antitumor therapy targeting lymphangiogenesis in ICC are still rare, the results of our study may provide a novel view of treatment for ICC.

This study provides a great deal of information about the critical influence of tumor-associated lymphangiogenesis on prognosis of hepatic resected patients with ICC. However, there are a few underlying limitations that remain to be confirmed. Firstly, limited number of patients may cause bias of the results, which could be improved by additional large-scaled studies. Secondly, the involved patients were local malignancies within the liver, patients with advanced and metastatic tumors may result in different outcomes. Lastly, all the involved patients were from Eastern countries, further confirmations by patients from other regions are needed.

Conclusion {#Sec14}
==========

High extent of tumor-associated lymphangiogenesis is significantly associated with lymph node metastasis and recurrence of the tumor in ICC. MLVD, a indicative factor for the extent of tumor-associated lymphangiogenesis, was found to be an independent prognostic factor for overall and recurrence-free survival in patients with ICC after resection. Evaluation of tumor-associated lymphangiogenesis by intraoperative biopsy seems promising to possess a great potential to improve survival outcomes by providing guidance to patient selection who may benefit from lymphadenectomy. We call for future large-scale prospective trials to verify our results for general application in real-world clinical medicine.
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